Back to Interventions
Substance / Medication

Danaparoid

SNOMED 372564002UMLS C0259507

Overview

Active Ingredient
danaparoid
RxNorm CUI
78484

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Pulmonary embolism
Venous thrombosis
Thrombocytopenic disorder
Thromboembolic disorder

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Hemoglobin

LOINC 718-7

secondary

Leukocytes

LOINC 26464-8

secondary

Platelets

LOINC 777-3

primary

Clinical Trials

44 trials linked to this intervention

44
Total Trials
14
Recruiting
7
With Results

Recent Trials

Evaluation of Argatroban Injection in Pediatric Patients Requiring Anticoagulant Alternatives to Heparin

NCT00039858Phase 4Completed24 enrolled

International Multi Centre Randomized Clinical Trial Of Anticoagulation In Children Following Fontan Procedures

NCT00182104Phase 4Completed111 enrolled

Trial of the Effect of Low-Molecular-Weight Heparin (LMWH) Versus Warfarin on Mortality in the Long-Term Treatment of Proximal Deep Vein Thrombosis (DVT) (Main LITE Study)

NCT00203580Phase 4Completed910 enrolled

Assessment of Long-Term Out-of-Hospital Treatment of Patients With Proximal Deep Vein Thrombosis (DVT) Using Low-Molecular-Weight Heparin (LMWH) Versus LMWH Followed by Warfarin

NCT00203658Phase 4Completed400 enrolled

Cystic Fibrosis and Totally Implantable Vascular Access Devices

NCT00244270Phase 4Completed97 enrolled
View all 44 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:
Treatment of 51 pregnancies with danaparoid because of heparin intolerance.
Lindhoff-Last Edelgard, Kreutzenbeck Hans-Joachim, Magnani Harry N · Thromb Haemost · 2005
PMID: 15630492Meta-Analysis
Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
Boissier Elodie, Senage Thomas, Babuty Antoine et al. · Anesth Analg · 2021
PMID: 32833716Observational
Comparison of Danaparoid Sodium and Synthetic Protease Inhibitors for the Treatment of Disseminated Intravascular Coagulation Associated with Hematological Malignancies: A Retrospective Analysis.
Minakata Daisuke, Fujiwara Shin-Ichiro, Hayakawa Jin et al. · Acta Haematol · 2020
PMID: 31461700Observational
Effects of argatroban, danaparoid, and fondaparinux on trombin generation in heparin-induced thrombocytopenia.
Tardy-Poncet Brigitte, Combe Marion, Piot Michèle et al. · Thromb Haemost · 2013
PMID: 23328916Observational
Danaparoid sodium attenuates the increase in inflammatory cytokines and preserves organ function in endotoxemic rats.
Iba Toshiaki, Miyasho Taku · Crit Care · 2008
PMID: 18601748ObservationalFull text (PMC)
[Multidisciplinary consultation for the prescription of danaparoid in suspected heparin-induced thrombocytopenia].
Verdy Elisabeth, Debrix Isabelle, Benomar Amina et al. · Presse Med · 2007
PMID: 17303370Observational
Results of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s.
Lubenow Norbert, Warkentin Theodore E, Greinacher Andreas et al. · Thromb Res · 2006
PMID: 15907979Observational
Safety and efficacy of danaparoid (Orgaran) use in children.
Bidlingmaier Christoph, Magnani Harry N, Girisch Monika et al. · Acta Haematol · 2006
PMID: 16549902Observational
Antithrombin ameliorates endotoxin-induced organ dysfunction more efficiently when combined with danaparoid sodium than with unfractionated heparin.
Iba Toshiaki, Kidokoro Akio, Fukunaga Masaki et al. · Intensive Care Med · 2005
PMID: 15995859Observational
A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity.
Takahashi Hidenori, Ebihara Satoru, Okazaki Tatsuma et al. · Br J Pharmacol · 2005
PMID: 16041398ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

NUCC 207RH0000X
Find a Provider

Health Goals

Goals connected through associated conditions

Optimize Iron and Blood Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Danaparoid (substance)
SNOMED CT
372564002
UMLS CUI
C0259507
RxNorm CUI
78484

Clinical Data

This intervention maps to 10 entities in the Ltrl knowledge graph.

4
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
44
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.